Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy
For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy,
